TOI Q1 revenue up 41% to $147.4M, net loss narrows to $2.5M

Oncology Institute, Inc.

2026-Q1 EPS reported -$0.02 revenue$147,441,000

Revenue $147.4M (+41% YoY); net loss $2.5M vs $19.6M loss prior year.
Adjusted EBITDA loss $2.4M improved from $5.1M loss; EPS $(0.02) vs $(0.21).
Specialty Pharmacy revenue up 78% YoY; record Part D fills.
Medicare Advantage lives to reach 200,000 in Florida effective July 1, 2026.
CMS Enhancing Oncology Model saved ~$2M in period 3; full-year guidance reaffirmed.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.965

Oncology Institute, Inc. reported three months ended March 31, 2026 results: revenue $147.4 million, net income $2.5 million, EPS $(0.02). Guidance reaffirmed.

Period: three months ended March 31, 2026
Revenue: $147.4 million
Net income: $2.5 million
EPS: $(0.02)
Guidance: reaffirmed
Result: reported results

Exact text from the filing

maintaining high-quality care. First Quarter 2026 Financial Highlights All comparisons are to the quarter ended March 31, 2025 unless otherwise noted • Consolidated revenue of $147.4 million increased 41.2% from $104.4 million • Gross profit of $23.3 million, increased 35.2% • Net loss of $2.5 million compared to net loss of $19.6 million • Basic and diluted (loss)

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

Oncology Institute, Inc. filing history →

Source: SEC EDGAR

accession 0001079973-26-000611

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.